icon-folder.gif   Conference Reports for NATAP  
 
 

IDweek

Back grey_arrow_rt.gif
 
 
 
Good In-Practice SVR12 With Sofosbuvir Regimens After HCV PI Failure in HIV/HCV Coinfected
 
 
  IDWeek2017/IDSA, October 4-8, 2017, San Diego
 
Mark Mascolini
 
HCV/HIV-coinfected patients in whom an HCV protease inhibitor (PI) had failed had a 93% 12-week sustained virologic response (SVR12) rate with a sofosbuvir-containing regimen in a small single-center analysis [1]. The SVR12 rate in this study is similar to that attained with ledipasvir/sofosbuvir in the ION-4 trial in treatment-experienced HCV/HIV patients [2].
 
Despite high SVR rates with DAA regimens in HCV/HIV-coinfected people, a fraction of DAA regimens fail and pose a retreatment challenge. Clinical researchers from Albany Medical Center conducted this retrospective review to determine clinical traits and SVR12 rates in HCV/HIV-coinfected people retreated with a sofosbuvir-containing regimen after failure of an HCV NS3/4a PI. Sofosbuvir is a nucleotide analog inhibitor of NS5B polymerase available as a single agent (Sovaldi) or coformulated with the HCV NS5A inhibitor ledipasvir (Harvoni).
 
The study involved patients with HCV genotype 1 and HIV whose last regimen included an HCV PI and failed. All got retreated with a sofosbuvir-containing combination between January 2014 and December 2015. Everyone had an undetectable HIV load when HCV retreatment began, and all received care from a primary provider who could refer patients to a hepatologist and to a pharmacist for medication review.
 
The analysis involved 14 people, 13 of them men, with ages ranging from 37 to 69. Eight people were white, 4 black, and 2 Hispanic. The failing regimen was telaprevir plus pegylated interferon (Peg-IFN)/ribavirin in 9, simeprevir/sofosbuvir in 2, and 1 each taking PegIFN/ribavirin/faldaprevir, PegIFN/ribavirin/simeprevir, or PegIFN/ribavirin/sofosbuvir. Seven of 14 people had F4 fibrosis, 1 was F2-F3, 3 were F2, 2 were F1, and 1 had an unknown fibrosis status.
 
Retreatment consisted of ledipasvir/sofosbuvir in 10, simeprevir/sofosbuvir in 2, ledipasvir/sofosbuvir/ribavirin in 1, and PegIFN/ribavirin/sofosbuvir in 1. Five people had to change their antiretrovirals when switching to the sofosbuvir regimen because of potential drug-drug interactions.
 
Thirteen people (93%) achieved SVR12 with retreatment and 1 was lost to follow-up after taking ledipasvir/sofosbuvir for 8 weeks. This response rate compares well with the SVR12 attained with ledipasvir/sofosbuvir in 185 previously treated HCV/HIV patients in the ION-4 trial, 96.8% [2]. Among 53 ION-4 participants who had already taken an HCV PI plus PegIFN/ribavirin, SVR12 with ledipasvir/sofosbuvir was 98.1%.
 
The Albany Medical Center researchers believe their findings "demonstrate that successful management of HIV/HCV coinfected patients can be done in a busy primary care HIV clinic using a multidisciplinary approach."
 
References
 
1. Gilroy SA, Choudhary M, Faragon J, Ells P, Kingsley Z. Treatment of HCV NS3/4a protease inhibitor experienced patients with sofosbuvir containing regimens in an outpatient clinic. IDWeek2017/IDSA. October 4-8, 2017. San Diego. Abstract 2228. https://idsa.confex.com/idsa/2017/webprogram/Handout/id5794/POSTER245_2228.pdf
 
2. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705-713. www.natap.org/2015/IAS/nejmoa1501315(1).pdf
 
--------------------------------
 
Treatment of HCV NS3/4a protease inhibitor experienced patients with sofosbuvir containing regimens in an Outpatient Clinic
 
Shelley A. Gilroy MD, Madhuchhanda Choudhary MD, John Faragon PharmD, Peter Ells MD, Zoe Kingsley RN, Joseph Cirabisi

1011171

1011172

1011173

1011174

1011175